Lutz Gieselmann

2.2k total citations
15 papers, 284 citations indexed

About

Lutz Gieselmann is a scholar working on Infectious Diseases, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lutz Gieselmann has authored 15 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 2 papers in Molecular Biology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lutz Gieselmann's work include SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (4 papers) and SARS-CoV-2 detection and testing (3 papers). Lutz Gieselmann is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (4 papers) and SARS-CoV-2 detection and testing (3 papers). Lutz Gieselmann collaborates with scholars based in Germany, United States and Austria. Lutz Gieselmann's co-authors include Florian Klein, Henning Gruell, Philipp Schommers, Meryem S. Ercanoglu, Christoph Kreer, Nico Pfeifer, Matthias Zehner, Christine Dahlke, Ralf Eggeling and Verena Krähling and has published in prestigious journals such as Nature Medicine, Nature Communications and PLoS ONE.

In The Last Decade

Lutz Gieselmann

14 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lutz Gieselmann Germany	10	183	70	53	47	47	15	284
Maddy L. Newby United Kingdom	13	225 1.2×	107 1.5×	71 1.3×	52 1.1×	88 1.9×	19	369
Matthew D. Slein United States	6	211 1.2×	43 0.6×	54 1.0×	74 1.6×	96 2.0×	9	302
Markus Mukenhirn Germany	7	221 1.2×	88 1.3×	40 0.8×	8 0.2×	104 2.2×	9	367
Caroline L. Ashley Australia	9	93 0.5×	100 1.4×	91 1.7×	18 0.4×	140 3.0×	15	300
Ludivine Grzelak France	7	194 1.1×	54 0.8×	28 0.5×	22 0.5×	100 2.1×	10	298
Yu-Hsin Wan United States	5	330 1.8×	110 1.6×	39 0.7×	78 1.7×	84 1.8×	6	396
Leah J. Homad United States	7	343 1.9×	105 1.5×	43 0.8×	57 1.2×	79 1.7×	9	417
Ellen L. Suder United States	4	224 1.2×	75 1.1×	57 1.1×	16 0.3×	70 1.5×	6	303
Virginia Chu United States	6	65 0.4×	150 2.1×	115 2.2×	10 0.2×	38 0.8×	6	368
Gabrielle Kelly Australia	7	116 0.6×	143 2.0×	17 0.3×	9 0.2×	42 0.9×	8	243

Countries citing papers authored by Lutz Gieselmann

Since Specialization

Citations

This map shows the geographic impact of Lutz Gieselmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lutz Gieselmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lutz Gieselmann more than expected).

Fields of papers citing papers by Lutz Gieselmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lutz Gieselmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lutz Gieselmann. The network helps show where Lutz Gieselmann may publish in the future.

Co-authorship network of co-authors of Lutz Gieselmann

This figure shows the co-authorship network connecting the top 25 collaborators of Lutz Gieselmann. A scholar is included among the top collaborators of Lutz Gieselmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lutz Gieselmann. Lutz Gieselmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bethe, Ullrich, Peter Borchmann, Veronica Di Cristanziano, et al.. (2025). Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study. JMIR Research Protocols. 14. e60675–e60675.

Gieselmann, Lutz, Pinkus Tober‐Lau, Jens Klotsche, et al.. (2023). Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests. Journal of Clinical Virology. 165. 105518–105518. 1 indexed citations

Weber, Timm, S. Rose, Kanika Vanshylla, et al.. (2023). Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool. Science Immunology. 8(89). eadk5845–eadk5845. 15 indexed citations

Radford, Caelan E., Philipp Schommers, Lutz Gieselmann, et al.. (2023). Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Cell Host & Microbe. 31(7). 1200–1215.e9. 17 indexed citations

Kreer, Christoph, Meryem S. Ercanoglu, Lutz Gieselmann, et al.. (2023). Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. Nature Communications. 14(1). 7137–7137. 7 indexed citations

Sommermann, Thomas, Xun Li, Lutz Gieselmann, et al.. (2023). LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells. Frontiers in Immunology. 14. 1331730–1331730. 14 indexed citations

Gieselmann, Lutz, Pinkus Tober‐Lau, Jens Klotsche, et al.. (2022). Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open. 8(2). e002639–e002639. 11 indexed citations

Ercanoglu, Meryem S., Lutz Gieselmann, Manuel Koch, et al.. (2022). No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. iScience. 25(3). 103951–103951. 6 indexed citations

Gieselmann, Lutz, Christoph Kreer, Meryem S. Ercanoglu, et al.. (2021). Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nature Protocols. 16(7). 3639–3671. 31 indexed citations

10.

Krähling, Verena, Sandro Halwe, Cornelius Rohde, et al.. (2021). Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies. Journal of Immunological Methods. 490. 112958–112958. 31 indexed citations

11.

Korenkov, Michael, Kanika Vanshylla, Ralf Eggeling, et al.. (2021). Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals. Journal of Clinical Microbiology. 59(9). e0089621–e0089621. 43 indexed citations

12.

Eberhardt, Kirsten Alexandra, Felix Dewald, Eva Heger, et al.. (2021). Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms. 9(4). 733–733. 19 indexed citations

13.

Kreer, Christoph, Matthias Döring, Meryem S. Ercanoglu, et al.. (2020). openPrimeR for multiplex amplification of highly diverse templates. Journal of Immunological Methods. 480. 112752–112752. 22 indexed citations

14.

Gieselmann, Lutz, Eike R. Hrincius, Stefanie Deinhardt‐Emmer, et al.. (2020). The influenza replication blocking inhibitor LASAG does not sensitize human epithelial cells for bacterial infections. PLoS ONE. 15(5). e0233052–e0233052. 2 indexed citations

15.

Zehner, Matthias, Verena Krähling, Hadas Cohen‐Dvashi, et al.. (2019). Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine. 25(10). 1589–1600. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact